Phase 2 Study To Investigate the Efficacy, Safety And Pharmacokinetics Of Ravidasvir In Combination With Ritonavir-boosted Danoprevir And Ribavirin In Treatment-naive Non-cirrhotic Taiwanese Patients Who Have Chronic Hepatitis C Genotype 1

Trial Profile

Phase 2 Study To Investigate the Efficacy, Safety And Pharmacokinetics Of Ravidasvir In Combination With Ritonavir-boosted Danoprevir And Ribavirin In Treatment-naive Non-cirrhotic Taiwanese Patients Who Have Chronic Hepatitis C Genotype 1

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Danoprevir (Primary) ; Ravidasvir (Primary) ; Ribavirin (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EVEREST
  • Sponsors Ascletis
  • Most Recent Events

    • 18 Jan 2018 Primary endpoint has been met. (Proportion of participants with Sustained Virologic Response 12 weeks after end of treatment (SVR12)) as per results published in the Journal of Gastroenterology and Hepatology
    • 18 Jan 2018 Results published in the Journal of Gastroenterology and Hepatology
    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top